drugset / Trial / NCT03636373
Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this pilot study is to investigate the safety and efficacy of etanercept (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to triamcinolone acetonide an FDA approved drug to treat acute gout attacks.
Timeline
- Start
- 2019-10-25
- Primary completion
- 2021-08-13
- Completion
- 2021-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | Subcutaneous |
| Comparator | Triamcinolone Acetonide | Other / unclassified | 40 mg | Intramuscular |